Head-to-head · WeighScore
Claya vs Teleios Health
The verdict
Claya takes it — 62.8/100 to 60.2/100.
Claya grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Claya is a direct-to-consumer telehealth platform offering compounded semaglutide and tirzepatide in both injectable and oral-tablet forms — a wider format range than most competitors.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Claya | Teleios Health |
|---|---|---|
| WeighScore | 62.8/100 | 60.2/100 |
| Grade | C | C |
| Scorecard rank | #267 | #328 |
| Semaglutide | $299/mo (compounded) | $99/mo (starting dose, compounded) |
| Tirzepatide | $299/mo (compounded) | $139/mo (starting dose, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #267 · C
Strengths
- Two named licensed clinicians (Habashy, NMD MS and Barber, MD PhD) — rare transparency for compounded GLP-1
- Two named pharmacy partners with full addresses (RedRock, UT and Healthware, KY)
- Both injectable and oral-tablet forms offered for semaglutide and tirzepatide
- Weight-loss money-back guarantee published on the homepage
- Free expedited shipping included in the monthly price
Where it loses points
- States-served list not disclosed — you must check at checkout
- LegitScript certification status not displayed
- Corporate legal entity not disclosed on the site or privacy policy
- Oral compounded tablets have weaker efficacy data than injectable semaglutide
- Intro pricing is higher at refill ($299), erasing the first-month advantage
Graded #328 · C
Strengths
- Compounded semaglutide from $99/mo — among the lowest floor prices in cash-pay telehealth
- Compounded tirzepatide from a competitive $139/mo floor
- Markets physician (MD/DO) prescribing rather than an NP-only model
- Clean meta-tag and SEO implementation
Where it loses points
- Single-page app: state availability, pharmacy partner, dose pricing, lab requirements, and refund policy aren't visible and couldn't be verified
- No named medical director, physician, or corporate entity disclosed
- Year founded unknown — a newer floor-price entrant warranting extra scrutiny
- No LegitScript, NABP, or SOC 2 trust signal found
- Heavy paid-acquisition ad-tech stack — pair with diligence on the clinical layer
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.